Rhythm Pharmaceuticals, the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Joseph Stringer from Needham maintained a Buy rating on the stock and has a $148.00 price target.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Joseph Stringer has given his Buy rating due to a combination of factors tied to Rhythm Pharmaceuticals’ recent performance and pipeline visibility. He points to the company’s preliminary fourth-quarter 2025 product revenue of $57 million, which, while in line with his own forecast, modestly exceeds Street expectations and demonstrates solid quarter-over-quarter growth. He also highlights that management reaffirmed key upcoming milestones, including pivotal Phase 3 EMANATE data and the Japanese cohort results in acquired hypothalamic obesity, as well as the March 20, 2026 PDUFA date for setmelanotide in aHO, which together support a clear and potentially value-creating catalyst path.
In his view, the growth outlook for the Bardet-Biedl syndrome (BBS) indication is strong enough to warrant higher revenue projections, which led him to raise his 2026 total revenue estimate to $293 million, largely on a steeper ramp for BBS. While he assumes a relatively cautious contribution from the hypothalamic obesity indication versus consensus, he still sees meaningful upside once U.S. approval is secured and real-world uptake becomes clearer. These factors, combined with increased confidence in the commercial trajectory and upcoming clinical and regulatory events, underpin his decision to raise the price target to $148 and maintain a Buy recommendation on the stock.
In another report released on January 6, Wells Fargo also maintained a Buy rating on the stock with a $129.00 price target.